Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side of the face caused by the compression of the facial/cranial nerve, with no known underlying pathological cause. Such a condition typically manifests in a unilateral paralysis of the face. In rare cases, both sides of the face can be affected. Bell’s palsy is characterised by its rapid onset, reaching clinical peak within 72 hours. Most patients fully recover from Bell’s palsy.
This report provides the current incident population for Bell’s palsy across 15 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, China, Turkey, Mexico, Denmark, Egypt and South Korea) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Bell’s palsy have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Bell’s palsy include:
• Rapid onset of mild weakness to total paralysis on one side of the face
• Facial droop
• Drooling
• Increased sensitivity to sound on the affected side
• Headache
• Synkinesis (involuntary facial movement)
• Decrease in taste sensations
• Pain around the jaw
• Pain behind the ear on the affected side
• Change in volume of tears/saliva that the individual may produce
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global Bell’s palsy market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of Bell’s palsy and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Bell’s palsy incident population.
• Identify sub-populations within Bell’s palsy which require treatment.
• Gain an understanding of the specific markets that have the largest number of Bell’s palsy patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line incidence for Bell’s palsy
• Features of Bell’s palsy patients
• Recurrence of Bell’s palsy
• Sequelae and features of Bell’s palsy patients
• Co-morbidities of patients with Bell’s palsy
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• The House-Brackmann Facial Nerve Grading System
• Incidence of Bell’s palsy, total (000s)
• Incidence of Bell’s palsy, males (000s)
• Incidence of Bell’s palsy, females (000s)
• Bell’s palsy patients by House-Brackmann Grade (at Onset), total (000s)
• Completeness of paralysis of face, total (000s)
• Recovery of Bell’s palsy patients, total (000s)
• Bell’s palsy patients experiencing recurrence, total (000s)
• Patients with recurrent Bell’s palsy by number of recurrent episodes, total (000s)
• Bell’s palsy patients that develop sequelae, total (000s)
• Severity of Sequelae, total (000s)
• Bell’s palsy patients with hypertension, total (000s)
• Bell’s palsy patients with diabetes mellitus, total (000s)
• Abbreviations and Acronyms used in the report
• USA Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• USA Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Canada Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Canada Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• France Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• France Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Germany Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Germany Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Italy Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Italy Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Spain Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Spain Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• UK Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• UK Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Brazil Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Brazil Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Japan Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Japan Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• China Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• China Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Turkey Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Turkey Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Denmark Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Denmark Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Mexico Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Mexico Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• Egypt Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• Egypt Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
• South Korea Incidence of Bell’s palsy by 5-yr age cohort, males (000s)
• South Korea Incidence of Bell’s palsy by 5-yr age cohort, females (000s)
